

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/036674-2022>

Award

Purchase of Apheresis Spectra Optia machines with maintenance and consumables

NHS Wales Shared Services Partnership

F15: Voluntary ex ante transparency notice

Notice identifier: 2022/S 000-036674

Procurement identifier (OCID): ocds-h6vhtk-039481

Published 29 December 2022, 3:01pm

Section I: Contracting authority/entity

I.1) Name and addresses

NHS Wales Shared Services Partnership

Procurement Services, Cardiff and Vale University Local Health Board, Woodlands House,
Maes-Y-Coed Road

Cardiff

CF14 4HH

Email

emma.lane@wales.nhs.uk

Telephone

+44 02921836450

Country

United Kingdom

NUTS code

UK - United Kingdom

Internet address(es)

Main address

<http://www.procurement.wales.nhs.uk>

Buyer's address

http://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Purchase of Apheresis Spectra Optia machines with maintenance and consumables

Reference number

CAV-STA (22-23) 5

II.1.2) Main CPV code

- 33140000 - Medical consumables

II.1.3) Type of contract

Supplies

II.1.4) Short description

NHS Wales Shared Services Partnership who are hosted by Velindre NHS Trust acting on behalf of Cardiff and Vale University Local Health Board wish to inform the market that they intend to award a contract for the purchase of three Apheresis Spectra Optia machines with maintenance and consumables.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £400,000

II.2) Description

II.2.2) Additional CPV code(s)

- 33194210 - Blood-transfusion devices

II.2.3) Place of performance

NUTS codes

- UKL22 - Cardiff and Vale of Glamorgan

II.2.4) Description of the procurement

The South Wales Blood and Marrow Transplant Programme (SWBMT) serves adults and children within the catchment area of mid, west and south Wales, comprising six of the seven Welsh Local Health Boards (LHBs), with a combined population of approximately 2.4 million and accounting for over three-quarters of the Welsh population.

The Children's oncology unit at the Children's Hospital for Wales (CHfW) is the only unit in Wales that provides treatment for children with complex haematological conditions (such as sickle cell anaemia or treatments requiring cell collection for re-infusion post chemotherapy). The unit works closely in partnership with the adult haematology department as the services are small and the processes required to manage the paediatric conditions are carried out rarely. Therefore education, training and maintaining competence are dependent on working in partnership with the adult service.

The three Spectra Optia machines required to carry out apheresis, cell collection or cell processing procedures in this speciality are now of an age where they require replacement. The machine carries out highly specialist processes so they have to be reliable and accurate.

This notice is for the purchase of three Spectra Optia machines including maintenance for up to five years (after the one year warranty) and consumables.

II.2.11) Information about options

Options: Yes

Description of options

Up to five years for maintenance (after the one year warranty) and consumables.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

- The procurement falls outside the scope of application of the regulations

Explanation:

The apheresis service at Cardiff and Vale UHB provides:

1. Donor apheresis (collection of haematopoietic progenitor cells [HPC, A] and peripheral blood mononuclear cells for immediate therapeutic use as well as a precursor for manufacture into chimaeric antigen receptor (CAR) T-cells) [MNC, A]

2. Therapeutic apheresis including plasma exchange and red blood cell exchange

NICE Medical Technologies Guidance [MTG28], published the 2nd March 2016 and updated August 2020, concluded, inter alia, that the Spectra Optia is effective for managing red blood cell exchange in managing sickle cell disease and further noted that use of the Spectra Optia is likely to result in significant cost savings in most patients with sickle cell disease. NICE further noted that adopting the Spectra Optia is estimated to result in cost savings per person per year. As a result of this Guidance, NHSE has adopted the Spectra Optia system for its apheresis services.

Given the need to perform both donor and therapeutic apheresis, It is imperative that the chosen platform is able to perform both functions effectively and efficiently. The Spectra Optia is the only system to have been reviewed and approved by NICE [MTG28] for therapeutic red cell exchange with resultant savings to the NHS. This is a service provided to the Health Board's patient population with sickle cell disease.

In addition, the Paediatrics department requires the same equipment throughout the Health Board to align with Adult services ensuring standardised patient treatment and care along with staff training. Any change in equipment would mean that staff would require retraining and through the initial transition there is a greater risk of use error due to unfamiliarity.

On the above basis, the Health Board is issuing this notice and applying a 10 day standstill period prior to award of the purchase of three machines and a contract for up to five years for maintenance (after the one year warranty) and consumables.

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V. Award of contract/concession

A contract/lot is awarded: Yes

V.2) Award of contract/concession

V.2.1) Date of conclusion of the contract

29 December 2022

V.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor/concessionaire

Terumo BCT Ltd

Old Belfast , Millbrook

Larne

BT402SH

Country

United Kingdom

NUTS code

- UKN0 - Northern Ireland

The contractor/concessionaire is an SME

No

V.2.4) Information on value of contract/lot/concession (excluding VAT)

Total value of the contract/lot/concession: £400,000

Section VI. Complementary information

VI.3) Additional information

The value stated in this notice is the higher ceiling contract figure and may not be fully utilised as this will be dependent upon the volume of consumables ordered and maintenance years taken up.

(WA Ref:127796)

VI.4) Procedures for review

VI.4.1) Review body

High Court

London

Country

United Kingdom

Internet address

<http://www.procurement.wales.nhs.uk>

VI.4.3) Review procedure

Precise information on deadline(s) for review procedures

NHS Wales Shared Services Partnership on behalf of Cardiff and Vale University Health Board will allow a minimum 10 calendar day standstill period between notifying the award decision and awarding the contract.